Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313050 · ClinicalTrials.gov registry record · Phase 2
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 511
- Enrollment target
NCT03313050 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 511 participants.
The verdict
NCT03313050, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 511 participants
- Enrollment target
Study Summary
This is a 2-stage, phase 1/2, randomized, active-controlled, observer-blinded study with a 2-arm parallel design in each stage. In Stage 1 healthy adults 50 to 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or a licensed tetanus, diphtheria, acellular pertussis combination vaccine (Tdap) (control group). In Stage 2 healthy adults 65 to 85 years of age previously vaccinated with Prevnar 13 \>=2 months prior to investigational product administration will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or the licensed 23-valent pneumococcal polysaccharide vaccine (control group).
Interventions
- BIOLOGICAL Multivalent
- BIOLOGICAL Tdap
- BIOLOGICAL polysaccharide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03313050
The ClinicalTrials.gov registry entry for NCT03313050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Multivalent is the first listed.
NCT03313050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03313050 about?
NCT03313050 is a clinical study titled "A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age". This is a 2-stage, phase 1/2, randomized, active-controlled, observer-blinded study with a 2-arm parallel design in each stage. In Stage 1 healthy adults 50 to 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of mul...
What is the current status of trial NCT03313050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 511 participants. The study started on 2017-10-12. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT03313050?
The interventions under investigation include: Multivalent (BIOLOGICAL), Tdap (BIOLOGICAL), polysaccharide (BIOLOGICAL).
Who is sponsoring clinical trial NCT03313050?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.